EUVIMEDEUVIMED entdecken
Open Access

Histopathological Outcomes of Thy3 Thyroid Nodules: Malignancy Risk in an Indeterminate Cytology Cohort

Paraskevi Karamitsou, Carlos Galan, Anant Patel, Ananth Vijendren, George Mochloulis, Panagiotis Dimitriadis

Cureus · 07.04.2026

DOI: 10.7759/cureus.106622 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cureus, erschienen am 07.04.2026. Verfasst von Paraskevi Karamitsou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ear, Nose and Throat (ENT), Lister Hospital, East and North Hertfordshire Teaching NHS Trust, Stevenage, GBR. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

fine needle aspirationthy3 thyroid nodulethyroid cancerthyroid cytologythyroid histology

Autor:innen und Institutionen

  • Department of Ear, Nose and Throat (ENT), Lister Hospital, East and North Hertfordshire Teaching NHS Trust, Stevenage, GBR.
  • Department of Ear, Nose and Throat (ENT), University of Navarra Clinic, Madrid, ESP.

Zitieren

APA

Karamitsou, P., Galan, C., Patel, A., Vijendren, A., Mochloulis, G., & Dimitriadis, P. (2026). Histopathological Outcomes of Thy3 Thyroid Nodules: Malignancy Risk in an Indeterminate Cytology Cohort. Cureus. https://doi.org/10.7759/cureus.106622

Vancouver

Karamitsou P, Galan C, Patel A, Vijendren A, Mochloulis G, Dimitriadis P. Histopathological Outcomes of Thy3 Thyroid Nodules: Malignancy Risk in an Indeterminate Cytology Cohort. Cureus. 2026. doi:10.7759/cureus.106622

BibTeX
@article{Karamitsou2026,
  author = {Karamitsou, Paraskevi and Galan, Carlos and Patel, Anant and Vijendren, Ananth and Mochloulis, George and Dimitriadis, Panagiotis},
  title = {Histopathological Outcomes of Thy3 Thyroid Nodules: Malignancy Risk in an Indeterminate Cytology Cohort},
  journal = {Cureus},
  year = {2026},
  doi = {10.7759/cureus.106622}
}
Kostenlos starten →